The New Label for Erythropoiesis Stimulating Agents: The FDA'S Sentence

Seminars in Dialysis

Volumn 25, Issue 3, 2012, Pages 263-266

  Fishbane, Steven ^a   Jhaveri, Kenar D ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; HEMOGLOBIN B; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; ARTICLE; BLOOD; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ERYTHROPOIESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PRESCRIPTION; RENAL REPLACEMENT THERAPY; STANDARD; UNITED STATES;

ANEMIA; DRUG PRESCRIPTIONS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84861230354     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2012.01065.x     Document Type: Article

References (15)

1. Available at, accessed December 28, 2011
2. Available at, accessed December 27, 2011
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339(9):584-590, 1998
4. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085-2098, 2006
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019-2032, 2009
6. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17(4):1181-1191, 2006
7. Collins AJ, Ma JZ, Ebben J: Impact of hematocrit on morbidity and mortality. Semin Nephrol 20(4):345-349, 2000
8. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16(7):2180-2189, 2005
9. Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, Gitlin M, Mayne TJ: Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 14:168-173, 2010
10. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071-2084, 2006
11. Fishbane S, Nissenson AR: Anemia management in chronic kidney disease. Kidney Int Suppl 72(117):S3-S9, 2010
12. Singh AK: Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int 80(6):569-571, 2011
13. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74(6):791-798, 2008
14. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH: Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med 171(20):1854-1856, 2011
15. Ifudu O, Valcourt JS: Does uraemia potentiate bacteraemia-associated haemolysis in patients receiving erythropoietin? Nephrol Dial Transplant 14(2):517-519, 1999